StreetInsider.com News Articles

Form 8-K REGENERON PHARMACEUTICAL For: Jun 12

Wed, 17 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260617/26659875.html

Form 8-K REGENERON PHARMACEUTICAL For: Jun 12

Wed, 17 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260617/26659875.html

Regeneron to present clinical data at medical conferences

Thu, 04 Jun 2026 07:00:50 -0400

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) will present clinical data from its metabolic disease, ophthalmology and rare disease pipelines at the American Diabetes Association 86th Scientific Sessions and the Endocrine Society Annual Meeting in June 2026.

The presentations include four abstracts at the ADA meeting focusing on muscle biology and body composition in metabolic disease. Three abstracts examine results from the Phase 2 COURAGE trial studying trevogrumab, an anti-GDF8 treatment, on lean mass in people with obesity treated with semaglutide.

At the ENDO meeting, Regeneron will present five abstracts, including Phase 3 clinical data for garetosmab as a treatment for fibrodysplasia ossificans progressiva

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Thu, 04 Jun 2026 07:00:00 -0400

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs

TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and research from its metabolic disease, ophthalmology and rare disease pipelines will be presented at two major medical meetings in June 2026. These include the American Diabetes Association (ADA) 86th Scientific Sessions, June 5-8 in New Orleans, and the Endocrine Society Annual Meeting (ENDO 2026), June 13-16 in Chicago.

“Our presentations at ADA and ENDO reflect the rapid progress

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Thu, 04 Jun 2026 07:00:00 -0400

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs

“Our presentations at ADA and ENDO reflect the rapid progress

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Thu, 04 Jun 2026 07:00:00 -0400

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs

“Our presentations at ADA and ENDO reflect the rapid progress

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Thu, 04 Jun 2026 07:00:00 -0400

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs

“Our presentations at ADA and ENDO reflect the rapid progress

WHO recommends Regeneron antibody for Bundibugyo Ebola outbreak

Thu, 28 May 2026 16:01:32 -0400

The World Health Organization has recommended maftivimab, a component of Regeneron Pharmaceuticals' (NASDAQ: REGN) Ebola treatment Inmazeb, for evaluation in clinical trials to address the current Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo and Uganda.

Maftivimab represents the most potent neutralizing antibody in Inmazeb, which was approved by the U.S. Food and Drug Administration in 2020 for treating Zaire ebolavirus infections. Laboratory studies have shown maftivimab demonstrates activity against multiple Ebola species, including Bundibugyo, though it has not been tested as a standalone treatment for this specific virus strain in living subjects.

The WHO declared the current Bundibugyo outbreak

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:00:00 -0400

Inmazeb^® (a three-antibody cocktail consisting of maftivimab, atoltivimab and odesivimab-ebgn) was the first Ebola treatment approved by the U.S. Food and Drug Administration, indicated specifically for the Orthoebolavirus zairense species, and has been administered to hundreds of patients

Maftivimab, the most potent neutralizing antibody in Inmazeb, has shown broad activity in vitro against multiple Ebola species, including Bundibugyo

Maftivimab has been recommended to be studied as a monotherapy in the current outbreak

TARRYTOWN, N.Y., May 28, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that maftivimab, the most potent neutralizing antibody included in Inmazeb^®

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

Thu, 28 May 2026 16:00:00 -0400

Maftivimab, the most potent neutralizing antibody in Inmazeb, has shown broad activity in vitro against multiple Ebola species, including Bundibugyo

Maftivimab has been recommended to be studied as a monotherapy in the current outbreak

TARRYTOWN, N.Y., May 28, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that maftivimab, the most potent neutralizing antibody included in Inmazeb^®

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit

Notice to Long-Term Shareholders of Commvault Systems, Inc. (NASDAQ: CVLT); MongoDB, Inc. (NASDAQ: MDB); New Era Energy & Digital, Inc. (NASDAQ: NUAI); and Regeneron Pharmaceuticals, Inc. (NASDAQ: REG

Wed, 27 May 2026 08:36:18 -0400

PHILADELPHIA, May 27, 2026 (GLOBE NEWSWIRE) --

Commvault Systems, Inc. (NASDAQ: CVLT):

Grabar Law Office is investigating claims on behalf of shareholders of Commvault Systems, Inc. (NASDAQ: CVLT). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.

If you purchased Commvault Systems, Inc. (NASDAQ: CVLT) shares prior to April 29, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit